The proposed rule amendment reduces regulatory burdens placed on insurers under existing provisions of the rule. In the case of medical bills for pharmaceuticals or pharmaceutical services provided by a pharmacy or pharmacist under Chapter 465, F.S., the insurer, service company/TPA or any entity acting on behalf of the insurer, would be relieved of the obligation of issuing an Explanation of Bill Review (“EOBR”) to that pharmacy or pharmacist if there is a preexisting contract between the two that governs and specifies the amount of reimbursement due on the medical bill.